At a glance
Effects
- Blood pressure reduction: Potent and sustained 24-hour BP lowering via AT1 receptor blockade; superior end-of-dosing-interval control versus other antihypertensives in head-to-head trials [3].
- Cardiovascular risk reduction: Reduces risk of stroke, heart attack, and all-cause mortality in patients aged ≥55 with cardiovascular risk factors [4][5].
- Insulin sensitivity / metabolic benefit: PPARγ agonism improves insulin sensitivity, reduces visceral fat, and raises serum adiponectin in hypertensive patients [3].
- Kidney protection: ARB class reduces progression of diabetic nephropathy and protects against end-organ damage in patients with diabetes and hypertension [1].
- Left ventricular remodelling: Meta-analysis data suggest telmisartan may reduce left ventricular mass index beyond its BP-lowering effect [3].
Angiotensin II Receptor Blocker (ARB) + partial PPARγ agonist
~24 hours (longest in ARB class; supports once-daily dosing)
Oral tablet (20 mg, 40 mg, 80 mg)
Peak plasma concentration 0.5–1 hour post-dose; steady state in 5–7 days
ABSOLUTELY contraindicated — FDA black-box fetal toxicity warning
About Telmisartan
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Telmisartan is a prescription angiotensin II receptor blocker (ARB) used to treat hypertension and to reduce the risk of cardiovascular events such as stroke and heart attack [1][2]. It is one of the most pharmacologically distinct ARBs, distinguished by the longest plasma half-life, highest lipophilicity, and strongest AT1 receptor binding affinity in its class [3].
How it works
Telmisartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing angiotensin II from constricting blood vessels and stimulating aldosterone release — both of which raise blood pressure [1]. This causes vasodilation and reduces sodium/water retention, lowering blood pressure [1]. Uniquely among ARBs, telmisartan also acts as a partial agonist of PPARγ (peroxisome proliferator-activated receptor gamma), which contributes additional anti-inflammatory, insulin-sensitising, and visceral-fat-reducing effects beyond its blood-pressure action [2][3].
Risks & side effects
Most important: Telmisartan carries an FDA black-box warning: drugs acting on the renin-angiotensin system can cause fetal injury or death — it must not be used during pregnancy and must be stopped immediately if pregnancy is detected [6][7]. Additionally, in volume-depleted or salt-depleted individuals, symptomatic hypotension can occur shortly after starting the drug [7].
Common
Serious
- Hyperkalemia (dangerously elevated serum potassium) — risk increases with renal impairment or concurrent RAAS-blocking drugs [7][11]
- Acute kidney injury / renal impairment — especially in volume-depleted, elderly, or renin-dependent patients [11]
- Symptomatic hypotension — particularly in patients on diuretics or with dehydration [7]
- Fetal toxicity / fetal death — absolute contraindication in pregnancy (FDA black-box warning) [6]
Rare
- Angioedema (severe swelling of face, tongue, or throat) [9]
- Severe allergic / anaphylactic reaction [9]
- Hepatic dysfunction — plasma concentrations markedly elevated in hepatic insufficiency [12]
- Digoxin toxicity — telmisartan raises digoxin peak plasma concentration ~49% when co-administered [7]
- Lithium toxicity — reversible increases in serum lithium reported with concurrent use [7]
Safety & harm reduction
- Blood pressure — regularly throughout treatment [8]
- Serum potassium — monitor for hyperkalemia, especially with renal impairment or concurrent RAAS agents [7][11]
- Renal function (serum creatinine, eGFR) — especially when starting therapy, in elderly patients, or if volume-depleted [11]
- Digoxin plasma levels — telmisartan raises digoxin concentration ~49% at peak [7]
- Liver function — use with caution in hepatic insufficiency; bioavailability approaches 100% in this context [12]
- ACE inhibitors / other ARBs — dual RAAS blockade significantly increases risk of hypotension, hyperkalemia, and renal failure; avoid combination [11]
- Aliskiren — contraindicated in diabetics; use with caution in all patients [11]
- NSAIDs (ibuprofen, naproxen, etc.) — reduce antihypertensive effect and increase risk of kidney damage [9]
- Digoxin — telmisartan increases peak digoxin plasma concentrations by ~49% and trough by ~20%; monitor digoxin levels [7]
- Lithium — reversible increases in lithium levels and toxicity reported; monitor carefully [7]
- Potassium-sparing diuretics / potassium supplements — additive hyperkalemia risk [11]
- Other antihypertensive agents / diuretics — additive blood pressure lowering; risk of symptomatic hypotension [7]
- Start at the lowest effective dose (commonly 20–40 mg once daily) and titrate based on blood pressure response [12]
- Correct volume or salt depletion before initiating therapy to reduce risk of symptomatic hypotension [7]
- Do not abruptly discontinue — taper under medical supervision if stopping long-term use
- If used alongside anabolic/androgenic compounds that raise blood pressure, ensure BP monitoring is frequent and dose adjusted accordingly
- Hepatic impairment: use with extreme caution; bioavailability approaches 100% and normal doses may cause excessive exposure [12]
Dosage context
FDA-approved dosing (commonly reported, not a prescription): for hypertension, 20–80 mg orally once daily; for cardiovascular risk reduction, 80 mg once daily [12]. The pharmacokinetics are nonlinear — plasma concentrations increase disproportionately at higher doses, so dose escalation should be cautious [12]. Steady state is reached in 5–7 days of once-daily dosing [10]. Note: dosing outside medical supervision (e.g. as a performance adjunct for BP management on AAS cycles) is not clinically endorsed and individual response varies significantly.
Sources
- 1.Patsnap — Telmisartan Mechanism of Action
- 2.ClinicalTrials.gov — Telmisartan GVHD Study Protocol (PPARγ / ROCK mechanism)
- 3.ScienceDirect — Telmisartan Overview (half-life, lipophilicity, PPARγ)
- 4.NCBI PMC — Comparative Effectiveness of Telmisartan vs Other ARBs (real-world outcomes)
- 5.Drugs.com — Telmisartan Uses, Side Effects & Warnings
- 6.FDA Prescribing Information — Micardis (Telmisartan) Label 2009
- 7.ClinicalTrials.gov — COVID-19 Telmisartan Safety Protocol (contraindications, interactions)
- 8.MedCentral — Telmisartan Monograph (adverse events ≥1%)
- 9.GoodRx — Telmisartan Side Effects
- 10.DailyMed — Telmisartan Tablet Label (pharmacokinetics)
- 11.NBInno — Telmisartan Side Effects and Interactions (physician's guide)
- 12.Drugs.com Professional — Telmisartan Package Insert / Prescribing Information
- 13.PubMed — Pharmacokinetics of Telmisartan in Healthy and Hypertensive Subjects
- 14.DrugBank — Telmisartan Drug Entry
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Telmisartan· 2 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
Driada | blister-pack | 20 mg/tab | 100 tab | 39,90 € | €0.020/mg |
GenericSelected | blister-pack | 80 mg/tab | 140 tab | 98,90 € | ★€0.009/mg |
Substance reviews(1)
Independent reviews of this compound from the wider market — about the substance, not our delivery.
- ★★★★★5 months ago
Excellent customer service. Stealth, quality highly recommended